This is not the most recent version of the article. View current version (9 APR 2015)

Intervention Review

You have free access to this content

Pharmacological treatment for pain in Guillain-Barré syndrome

  1. Jia Liu1,*,
  2. Lu-Ning Wang1,
  3. Ewan D McNicol2

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 20 OCT 2013

Assessed as up-to-date: 27 AUG 2012

DOI: 10.1002/14651858.CD009950.pub2


How to Cite

Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD009950. DOI: 10.1002/14651858.CD009950.pub2.

Author Information

  1. 1

    Chinese PLA General Hospital, Department of Geriatric Neurology, Beijing, China

  2. 2

    Tufts Medical Center, Departments of Anesthesiology and Pharmacy, Boston, Massachusetts, USA

*Jia Liu, Department of Geriatric Neurology, Chinese PLA General Hospital, Fuxing Road 28, Beijing, 100853, China. Jason_liu1984@163.com.

Publication History

  1. Publication Status: New
  2. Published Online: 20 OCT 2013

SEARCH

This is not the most recent version of the article. View current version (09 APR 2015)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Pandey 2002 {published data only}
  • Pandey CK, Bose N, Garg G, Singh N, Baronia A, Agarwal A, et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesthesia and Analgesia 2002;95(6):1719-23. [PUBMED: 12456446]
Pandey 2005 {published data only}
  • Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Anesthesia and Analgesia 2005;101(1):220-5. [PUBMED: 15976235]
Ruts 2007 {published data only}
  • Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA. Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. Journal of Neurology 2007;254(10):1318-22. [PUBMED: 17426908]

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Brisby 2002 {published data only}
Forsberg 2004 {published data only}
  • Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Widén Holmqvist L, Swedish Epidemiological Study Group. Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study. Journal of the Neurological Sciences 2004;227(1):131-8.
Korinthenberg 2005 {published data only}
  • Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005;116(1):8-14.
Morgenlander 1990 {published data only}
Odaka 2005 {published data only}
  • Odaka M, Tatsumoto M, Hoshiyama E, Hirata K, Yuki N. Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barré syndrome. European Neurology 2005;53(4):194-6.
Tripathi 2000 {published data only}

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Anand 2011
  • Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. British Journal of Anaesthesia 2011;107(4):490-502.
Asbury 1990
Bennett 2004
Berciano 2000
Dworkin 2008
  • Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain 2008;9(2):105-21.
Egger 1997
Ennis 1991
Eroglu 2009
  • Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009;139(2):380-92.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hughes 2005a
Hughes 2005b
Israeli 2012
  • Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. Guillain-Barré syndrome-a classical autoimmune disease triggered by infection or vaccination. Clinical Reviews in Allergy and Immunology 2012;42(2):121-30.
McGrogan 2009
Moore 2010
  • Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain-establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9.
Moore 2011
  • Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2]
Moore 2012
Moulin 1997
Pentland 1994
Peterson 2010
  • Peterson K, McDonagh M, Thakurta S, Dana T, Roberts C, Chou R, et al. Drug class review: cyclo-oxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): final update 4 report. www.ncbi.nlm.nih.gov/books/NBK53955/ (accessed 17 January 2012).
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Ruts 2010
  • Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, et al. Dutch GBS Study Group. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology 2010;75(16):1439-47.
Sawynok 2001
  • Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. Journal of Psychiatry and Neuroscience 2001;26(1):21-9.
Sullivan 2006
  • Sullivan MD, Robinson JP. Antidepressant and anticonvulsant medication for chronic pain. Physical Medicine and Rehabilitation Clinics of North America 2006;17(2):381-400.
van Koningsveld 2004
  • van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J, van Doorn PA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome:randomised trial. Lancet 2004;363(9404):192-6.
Woolf 1999
Zöllner 2008

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Liu 2012
  • Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD009950]